Vital Pharmaceuticals, Inc. v. Christopher Alfieri

23 F.4th 1282
CourtCourt of Appeals for the Eleventh Circuit
DecidedJanuary 20, 2022
Docket20-14217
StatusPublished
Cited by37 cases

This text of 23 F.4th 1282 (Vital Pharmaceuticals, Inc. v. Christopher Alfieri) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vital Pharmaceuticals, Inc. v. Christopher Alfieri, 23 F.4th 1282 (11th Cir. 2022).

Opinion

USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 1 of 34

[PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________

No. 20-14217 ____________________

VITAL PHARMACEUTICALS, INC., a Florida corporation d.b.a. VPX Sports/Redline/Bang Energy, Plaintiff-Appellee-Cross Appellant, versus CHRISTOPHER ALFIERI, an individual, ANDREW LAROCCA, an individual, ELEGANCE BRANDS, INC., a Delaware corporation,

Defendants-Cross Appellees, USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 2 of 34

2 Opinion of the Court 20-14217

ADAM PERRY, an individual,

Defendant,

AMY MAROS, an individual,

Defendant-Appellant-Cross Appellee.

Appeals from the United States District Court for the Southern District of Florida D.C. Docket No. 0:20-cv-61307-AHS ____________________

Before WILLIAM PRYOR, Chief Judge, GRANT, and ANDERSON, Cir- cuit Judges. WILLIAM PRYOR, Chief Judge: This appeal and cross-appeal involve the partial grant and partial denial of a motion for a preliminary injunction to enforce several restrictive covenants against the former employees of a pro- ducer of energy drinks. One former employee argues on appeal that she should not have been enjoined. The producer argues on USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 3 of 34

20-14217 Opinion of the Court 3

cross-appeal that the district court should have enjoined additional former employees. Many, but not all, of the restrictive covenants—and the cor- responding provisions in the preliminary injunction—have ex- pired. So, we dismiss as moot the portions of the former em- ployee’s appeal that challenge the expired provisions. We also dis- miss as moot the entire cross-appeal, which concerns only the ex- pired covenants. But we have jurisdiction over—and reach the merits of—the former employee’s appeal from the unexpired pro- visions in the preliminary injunction. And we vacate those provi- sions because the producer failed to prove its entitlement to pre- liminary relief. I. BACKGROUND Vital Pharmaceuticals, Inc., a Florida corporation, produces and sells energy-drink products under the brand name “BANG.” It views itself as a competitor of “[c]ompanies such as . . . Red Bull, Rock Star[,] and Monster Energy.” And it considers itself “a recog- nized leader in the energy drink and sports nutrition markets.” In 2019, Vital made four hires relevant here. It hired Chris- topher Alfieri as vice-president of sales and distribution. It hired Adam Perry as director of sales and distribution. It hired Andrew LaRocca as director of distribution strategy. And it hired Amy Ma- ros as senior supply chain manager. When they accepted the job offers, these individuals signed employment agreements containing three restrictive covenants. USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 4 of 34

4 Opinion of the Court 20-14217

They agreed not to work for “a [c]ompeting [c]ompany” “[d]uring the term of [their] employment with [Vital] . . . and for a period of one . . . year from [their] termination or cessation date.” They agreed not to solicit Vital employees to join a competing company, a provision that was also valid for one year from termination. And they agreed “never to disclose” or “to utilize for [their] own benefit, or for any third party’s benefit” any of Vital’s confidential infor- mation, including its product formulae and its marketing and sales information. The new hires did not remain at the company for long. Vital terminated Alfieri in March 2020 when its business plans changed. Alfieri then joined Elegance Brands, Inc., a Delaware corporation, as its chief revenue officer. Elegance principally sells alcoholic bev- erages, but in 2019 it developed a cannabidiol-infused caffeinated drink called “Gorilla Hemp.” LaRocca and Perry left Vital in May 2020 and accepted jobs with Elegance. Maros resigned from Vital effective June 17, 2020, but it appears that she began working for Elegance in early June. Vital sued Alfieri, LaRocca, Maros, Perry, and Elegance. It alleged that the individuals violated their non-compete covenants by working for Elegance within a year after leaving Vital; that Al- fieri violated the employee non-solicitation covenant by encourag- ing LaRocca, Maros, and Perry to join Elegance; and that Elegance and Alfieri engaged in tortious interference with Vital’s contractual relationships with the other former employees. Vital sought in- junctive relief and damages. USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 5 of 34

20-14217 Opinion of the Court 5

Vital then moved for a preliminary injunction. It asked the district court to enjoin its former employees from violating their non-compete covenants by working for Elegance or another com- petitor during the one-year term of those covenants, “as such pe- riod may be extended due to tolling.” It also sought to enforce Al- fieri’s employee non-solicitation covenant. And it asked that Ele- gance be enjoined from interfering with the former employees’ re- strictive covenants and from using any confidential information be- longing to Vital. Perry settled with Vital before the district court ruled on the motion. After a two-day evidentiary hearing, the district court granted the motion in part. It first determined that the restrictive covenants were valid and enforceable under Florida law. See FLA. STAT. § 542.335. Specifically, it concluded that the covenants were justified by Vital’s “legitimate business interests” in its product for- mulae, in its other confidential information, and in its customer re- lationships. See id. § 542.335(1)(b). And it rejected the argument that Vital was required to “identify specific customers” to establish a legitimate business interest in its customer relationships. The district court then concluded that Vital “ha[d] shown a substantial likelihood of succeeding on its claims against Maros . . . but not [against] Alfieri or LaRocca.” It explained that Vital had “presented . . . more than sufficient evidence . . . that Maros ha[d] breached the [agreement] she signed” because the evidence estab- lished that “Maros accepted a position at Elegance while still em- ployed [by] and collecting [a] salary from [Vital].” And it reasoned USCA11 Case: 20-14217 Date Filed: 01/20/2022 Page: 6 of 34

6 Opinion of the Court 20-14217

that it could infer a likelihood of success from the breach of the restrictive covenant. But, crediting the testimony of Elegance’s chief executive officer, the district court found that “there [was] ab- solutely no evidence that Alfieri or LaRocca took any information with them from [Vital] to Elegance” or that Elegance had seen any of Vital’s confidential information. So, Vital could not “make a prima facie showing that Alfieri or LaRocca breached their [agree- ments].” The district court also determined that Vital had satisfied the other elements necessary to secure a preliminary injunction against Maros. Under Florida law, the district court explained, Vital was entitled to a “presumption of irreparable injury” because it had proved “[t]he violation of an enforceable restrictive covenant,” id. § 542.335(1)(j), and Maros had not rebutted the presumption. The balancing of harms favored Vital because the district court was un- able to “consider any individualized economic or other hardship that might be caused to the person against whom enforcement is sought.” See id. § 542.335(1)(g)(1). The public interest favored the enforcement of the restrictive covenants. And Maros’s defenses to enforcement failed. The preliminary injunction contained five operative provi- sions. First, Maros was “enjoined for a period of twelve . . . months,” “calculated from” the date Vital posted a bond, “from working for Elegance” or other competitors of Vital.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sonny Ramdeo v. United States
Eleventh Circuit, 2025
Planned Parenthood v. State
2024 MT 227 (Montana Supreme Court, 2024)
M.H. v. Commissioner, Georgia Dept. of Community Health
111 F.4th 1301 (Eleventh Circuit, 2024)
Waseem Daker v. Timothy Ward
Eleventh Circuit, 2024
Waseem Daker v. Brian Owens
Eleventh Circuit, 2024
Braxton v. Stokes
S.D. Alabama, 2024
Council v. Hamm
M.D. Alabama, 2024
Charles Baldwin v. Express Oil Change, LLC
87 F.4th 1292 (Eleventh Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
23 F.4th 1282, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vital-pharmaceuticals-inc-v-christopher-alfieri-ca11-2022.